Clinical Trials Sponsored by Immunicon

Total 30 results

Immunicon

Unknown

Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer (IMMC-06)

Neoplasm Metastasis | Colorectal Cancer

United States
Immunicon

Unknown

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy (IMMC-38)

Prostate Cancer | Hormone Refractory Prostate Cancer

United States
Immunicom Inc

Recruiting

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Non Small Cell Lung Cancer

Turkey
Immunitor LLC
Immunitor Inc.

Unknown

Tableted COVID-19 Therapeutic Vaccine (COVID-19)

Covid19

Canada, Mongolia
Immunitor LLC
Immunitor Inc.

Unknown

Open Label Trial of Immunotherapy for Advanced Liver Cancer (HCC)

Liver Cirrhosis | HCC

Mongolia
Immunicom Inc

Recruiting

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Advanced Breast Cancer

Poland, Turkey
Immunitor LLC

Unknown

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer (V3-P)

Pancreatic Cancer Non-resectable

Mongolia
Immunitor LLC

Unknown

Open Label Immunotherapy Trial for Breast Cancer (V3-MOMMO)

Breast Cancer

Mongolia
Immunitor LLC

Unknown

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5)

HCC | Hepatocellular Carcinoma | Liver Cancer

Mongolia
Immunitor LLC

Unknown

Open Label Immunotherapy of Myoma (V3-myoma)

Leiomyoma | Fibroma | Myoma;Uterus | Fibroid Uterus

Mongolia
Immunitor LLC

Unknown

Immunotherapy of Chronic Kidney Failure

Renal Failure Chronic

Mongolia
Immunitor LLC

Unknown

Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma (cholangio)

Cholangiocarcinoma

Mongolia
Immunitor LLC

Unknown

Open Label Immunotherapy Trial for Ovarian Cancer (V3-OVA)

Ovarian Cancer

Mongolia
Immunitor LLC

Unknown

Immunotherapy of Cervical Cancer With V3-Cervix (V3-Cervix)

Cervical Cancer

Mongolia
Immunitor LLC

Unknown

V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer (GBM)

Glioblastoma Multiforme | Glioma of Brain

Mongolia
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-1)

Multiple Sclerosis

Spain, United States, India, Mexico, Bulgaria, Georgia, Lithuania, Moldova, Republic of, North Macedonia, Jordan, Greece, Albania, Colombia, Montenegro, Ukraine, Lebanon
Immunic AG

Terminated

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis (CALDOSE-1)

Ulcerative Colitis

United States, Russian Federation, Serbia, Belarus, Netherlands, Spain, United Kingdom, Croatia, Poland, Albania, Bosnia and Herzegovina, Bulgaria, Czechia, Georgia, North Macedonia, Portugal, Romania, Turkey, Ukraine
Immunic AG

Terminated

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United Kingdom
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
Immunic AG

Active, not recruiting

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multiple Sclerosis

United States, Germany, Netherlands, Bulgaria, Serbia, Canada, Czechia, Moldova, Republic of, North Macedonia, Poland, Romania, Ukraine
Immunic AG

Active, not recruiting

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) (EMPhASIS)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Poland, Bulgaria, Romania, Ukraine
Immunitor LLC
Ekomed LLC

Unknown

Open Label Immunotherapy of Endometriosis

Endometriosis

Mongolia
Dutch Colorectal Cancer Group
Sanofi; Roche Pharma AG; Koningin Wilhelmina Fonds; Immunicon

Completed

Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Colorectal Cancer

Netherlands
Immunitor LLC
University of Stellenbosch; Lisichansk Regional Tuberculosis Dispensary; National... and other collaborators

Completed

TB Immunotherapy Trial With Heat-killed M. Vaccae (imm03)

Tuberculosis

Mongolia, Ukraine
Immunic AG
FGK Clinical Research GmbH

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

COVID-19

Bulgaria, Germany
Dr. Ronnie Shapira
Immunicom Inc. San Diego California, USA

Recruiting

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Triple Negative Breast Cancer | Stage IV Melanoma | Stage IV Non-small Cell Lung Cancer | Renal Cell Carcinoma Stage IV

Israel
Lisichansk Regional Tuberculosis Dispensary
National Medical University, Ukraine; Immunitor USA Inc.

Completed

Tuberculosis (TB) Immunotherapy Phase 2 Study (imm02)

Tuberculosis

Ukraine
Lisichansk Regional Tuberculosis Dispensary
National Medical University, Ukraine; Immunitor USA Inc.

Completed

Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients

Tuberculosis

Ukraine
University Hospitals Coventry and Warwickshire...
Immunic AG; University of Warwick; MODEPHARMA

Completed

IMU-838 and Oseltamivir in the Treatment of COVID-19 (IONIC)

Covid 19

United Kingdom
Immunitor LLC
Federal State Budget Institution Research Center for Obstetrics, Gynecology...

Unknown

Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity (V6)

Atherosclerosis

Mongolia

Clinical Trials Sponsored by Immunicon

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations